NCT04138849

Evaluate Safety, Pharmacokinetics and Pharmacodynamics of BBT-877 in Healthy Japanese Male

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of BBT-877 Following Single Doses in Healthy Japanese Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Bridge Biotherapeutics, Inc. · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This study will collect safety, pharmacokinetic, and pharmacodynamic data in Japanese male subjects in order to support development worldwide.

Conditions

• Healthy Participants

Interventions

Type	Name	Description
DRUG	BBT-877 single dose	Oral capsule, single dose.
DRUG	Placebo single dose	Oral capsule, single dose.

Timeline

• Start date: 2019-10-01
• Primary completion: 2019-10-25
• Completion: 2019-10-25
• First posted: 2019-10-25
• Last updated: 2020-01-18

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study